Enhanced brain distribution of Ginsenoside F1 via intranasal administration in combination with absorption enhancers

• Published in: International journal of pharmaceutics 2024-04, Vol.654, p.123930-123930, Article 123930
• Main Authors: Mao, Ying, Yuan, Weihua, Gai, Jiayi, Zhang, Yixuan, Wu, Shiwen, Xu, En-Yu, Wang, Luyao, Zhang, Xin, Guan, Jian, Mao, Shirui
• Format: Article
• Language: English
• Subjects: 2-Hydroxypropyl-beta-cyclodextrin; Absorption enhancer; Administration, Intranasal; Brain - metabolism; Brain distribution; Drug Delivery Systems - methods; Ginsenoside F1; Ginsenosides; Intranasal; Nasal Mucosa - metabolism; Polyethylene Glycols; Solutol HS 15; Stearic Acids
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.123930

[Display omitted] Ginsenoside F1 (GF1) is a potential drug candidate for the treatment of Alzheimer's disease. Nevertheless, its low oral bioavailability and poor solubility limit clinical application. By utilizing either a direct or indirect approach, intranasal administration is a non-invasive drug delivery method that can deliver drugs to the brain rapidly. But large molecule drug delivered to the brain through intranasal administration may be insufficient to reach required concentration for therapeutic effect. In this study, using GF1 as a model drug, the feasibility of intranasal administration in combination with absorption enhancers to increase brain distribution of GF1 was explored. First of all, the appropriate absorption enhancers were screened by in situ nasal perfusion study. GF1-HP-β-CD inclusion complex was prepared and characterized. Thereafter, in vivo absorption of GF1 after intranasal or intravenous administration of its inclusion complex with/without absorption enhancers was investigated, and safety of the formulations was evaluated. The results showed that 2% Solutol HS 15 was a superior absorption enhancer. HP-β-CD inclusion complex improved GF1 solubility by 150 fold. Following intranasal delivery, the absolute bioavailability of inclusion complex was 46%, with drug brain targeting index (DTI) 247% and nose-to-brain direct transport percentage (DTP) 58%. Upon further addition of 2% Solutol HS 15, the absolute bioavailability was increased to 75%, with DTI 315% and DTP 66%. Both nasal cilia movement and biochemical substances (total protein and lactate dehydrogenase) leaching studies demonstrated 2% Solutol HS 15 was safe to the nasal mucosa. In conclusion, intranasal administration combining with safe absorption enhancers is an effective strategy to enhance drug distribution in the brain, showing promise for treating disorders related to the central nervous system.